eye
photogallery1
photogallery2
About TelomEye

Pioneering Vision Restoration

TelomEye is a pioneering biopharmaceutical company dedicated to saving sight and revolutionizing eye care through transformative science. We are motivated by the millions affected by age-related eye diseases, driving us to develop breakthrough therapies that address unmet medical needs in ophthalmology and enhance patients’ quality of life.

Our journey began in 2017 in Istanbul, when ophthalmologist Dr. İskender Alkın Solmaz recognized the potential of telomere biology to combat presbyopia and other vision-threatening conditions. Building on the Nobel Prize-winning discovery of telomeres’ role in cellular aging, Dr. Solmaz and his team developed a novel approach: topical treatments, like eye drops, that could target aging eye tissues directly while minimizing systemic risks.

Since our founding in 2021 in Toronto, TelomEye has advanced a highly differentiated pipeline, leveraging proprietary formulations and rigorous science. Our lead program targets Fuchs’ Endothelial Corneal Dystrophy (FED), a progressive disease affecting 4% of the population, with the potential to slow or halt its progression—offering an alternative to invasive procedures like corneal transplantation.

Our milestones include securing $1 million in funding at a $10 million valuation, joining JLab Toronto’s prestigious biotech hub, and earning the “Most Inspiring Presentation” award at the 2024 Bio NJ conference from J.P. Morgan and Johnson & Johnson. Today, we are preparing for human trials in early 2026, with a goal to bring our groundbreaking treatment to market by 2027-2028.

TelomEye isn’t just developing a therapy—we’re building a future where vision loss is no longer inevitable.
Professional Team

Meet Our Experience Team Members

Iskender A. Solmaz, MD

Assistant Professor of Ophthalmology
Oculoplastic / Reconstructive Surgery

Isilay Kavadarli, MD

Cataract and Refractive Surgery
Corneal Transplantation

Serkan Yuksel

20+ years in pharma and
medical device industry

Kubilay Turkmen

20+ years in pharma industry
10+ years in telomere science

Patrick J. Rochette, PhD

Professor, Ophthalmology, Laval University
World renowned telomere scientist

Natalie A. Afshari, MD, FACS

Professor of Ophthalmology,
Chief, Division of Cornea and Refractive Surgery

Kathryn A. Colby, MD, PhD

Professor of Ophthalmology,
Cornea External Diseases & Refractive Surgery

Victor Perez

Professor of Ophthalmology,
Cornea and External Diseases

Winston Chamberlain, MD, PhD

Professor of Ophthalmology,
Cornea External Disease & Refractive Surgery

Sanjay Patel, MD

Professor of Ophthalmology,
Fuchs’ Dystrophy & Corneal Transplantation

Gary Novack, PhD

Vice Chair for Collaborative Research
UC Davis Advisor
Foundation Fighting Blindness President
PhamacoLogic Development Regulatory and Clinical Expert

Mehmet Ali Aydınlar

Founder and leader of Turkey's largest chain of private hospitals, Acibadem Healthcare Group
Chairman of the Board of Trustees of Acibadem University
Board member of IHH Healthcare

Arda Ural, MBA, PhD

Americas Sector Leader for Life Sciences at Ernst & Young LLP
SVP Marketing & Sales Eyetech Pharmaceuticals

Re-Pie VC

Re-Pie Asset Management was established in 2015 in Istanbul.
Re-Pie, continues its operations as a fully comprehensive asset
management company with a portfolio size of 1.65 billion USD.